Diabetes Moves Down the List of Priorities for Big Pharma


While Sanofi and other Big Pharma companies rush toward cutting-edge therapies that unleash the immune system to fight cancer or potentially cure DNA flaws, diabetes is moving down the list of priorities.

Sanofi is joining rivals such as GlaxoSmithKline Plc that have shaken up their approach to finding new blockbusters, moving swiftly into the lucrative oncology field and culling less promising programs. The French drugmaker said Thursday it’s accelerating 17 programs — almost half in cancer — and dropping more than a dozen others under development, including two in diabetes. The company also plans to expand in gene therapies, John Reed, the new research chief, said in an interview.

Source https://www.bloomberg.com/news/articles/2019-02-07/sanofi-sees-profit-rising-as-drugmaker-revamps-research